CRISPR Therapeutics AG Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | -$10.56 | $0.37 | -$1.36 |
| Q2 2024 | 5 | -$11.08 | $0.39 | -$1.43 |
| Q3 2024 | 14 | -$10.75 | $0.38 | -$1.38 |
| Q4 2024 | 17 | -$1.82 | -$0.11 | -$1.23 |
| Q1 2025 | 8 | -$1.60 | -$1.10 | -$1.37 |
| Q2 2025 | 5 | -$10.47 | $0.37 | -$1.35 |
| Q3 2025 | 4 | -$9.62 | $0.34 | -$1.24 |
| Q4 2025 | 5 | -$9.44 | $0.33 | -$1.22 |
| Q1 2026 | 3 | -$8.71 | $0.31 | -$1.12 |
| Q2 2026 | 4 | -$8.46 | $0.30 | -$1.09 |
| Q3 2026 | 3 | -$4.96 | $0.17 | -$0.64 |
| Q4 2026 | 4 | -$3.73 | $0.13 | -$0.48 |
CRISPR Therapeutics AG Earnings Date And Information
CRISPR Therapeutics AG last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-1.01 earnings per share for the quarter, topping analysts' consensus estimates of $-1.33 by $0.32. The company had revenue of 602,000 for the quarter and had revenue of 370.00 M for the year. CRISPR Therapeutics AG has generated $-2 earnings per share over the last year ($-1.94 diluted earnings per share) and currently has a price-to-earnings ratio of -18.41. CRISPR Therapeutics AG has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based on prior year's report dates.
CRISPR Therapeutics AG Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$1.33 | -$1.01 | 0.32 | $6.57 M | $602,000 |
| 08/05/2024 | Q2 2024 | -$1.37 | -$1.49 | -0.12 | $12.06 M | $517,000 |
| 05/08/2024 | Q1 2024 | -$1.63 | -$1.43 | 0.2 | $504,000 | |
| 02/21/2024 | Q4 2023 | -$0.07 | $1.12 | 1.19 | $200.00 M | |
| 11/06/2023 | Q3 2023 | -$1.98 | -$1.41 | 0.57 | $11.89 M | $0 |
| 08/07/2023 | Q2 2023 | -$2.18 | -$0.98 | 1.2 | $1.80 M | $70.00 M |
| 05/08/2023 | Q1 2023 | -$1.67 | -$0.67 | 1 | $100.00 M | |
| 02/21/2023 | Q4 2022 | -$2.32 | -$1.41 | 0.91 | $6,000 | |
| 11/01/2022 | Q3 2022 | -$2.30 | -$2.24 | 0.06 | $1.85 M | $94,000 |
| 08/08/2022 | Q2 2022 | -$2.23 | -$2.40 | -0.17 | $2.21 M | $158,000 |
| 05/09/2022 | Q1 2022 | -$1.91 | -$2.32 | -0.41 | $178,000 | |
| 02/15/2022 | Q4 2021 | -$1.74 | -$1.84 | -0.1 | $12.35 M | |
| 11/03/2021 | Q3 2021 | -$1.69 | -$1.67 | 0.02 | $1.23 M | $329,000 |
| 07/29/2021 | Q2 2021 | $3.52 | $10.01 | 6.49 | $900.19 M | $900.20 M |
| 04/27/2021 | Q1 2021 | -$1.45 | -$1.51 | -0.06 | $202,000 | |
| 02/16/2021 | Q4 2020 | -$1.23 | -$1.53 | -0.3 | $194,000 | |
| 10/28/2020 | Q3 2020 | -$1.17 | -$1.32 | -0.15 | $1.92 M | $148,000 |
| 07/27/2020 | Q2 2020 | -$0.92 | -$1.30 | -0.38 | $18.13 M | $44,000 |
| 04/28/2020 | Q1 2020 | -$1.09 | -$1.15 | -0.06 | $157,000 | |
| 02/12/2020 | Q4 2019 | -$0.63 | $0.53 | 1.16 | $77.02 M |
CRISPR Therapeutics AG Earnings: Frequently Asked Questions
-
When is CRISPR Therapeutics AG's earnings date?
CRISPR Therapeutics AG has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates.
-
Did CRISPR Therapeutics AG beat their earnings estimates last quarter?
In the previous quarter, CRISPR Therapeutics AG (:CRSP) reported $-1.01 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.33 by $0.32.
-
How can I listen to CRISPR Therapeutics AG's earnings conference call?
The conference call for CRISPR Therapeutics AG's latest earnings report can be listened to online.
-
How can I read CRISPR Therapeutics AG's conference call transcript?
The conference call transcript for CRISPR Therapeutics AG's latest earnings report can be read online.
-
How much revenue does CRISPR Therapeutics AG generate each year?
CRISPR Therapeutics AG (:CRSP) has a recorded annual revenue of $370.00 M.
-
How much profit does CRISPR Therapeutics AG generate each year?
CRISPR Therapeutics AG (:CRSP) has a recorded net income of $370.00 M. CRISPR Therapeutics AG has generated $-1.94 earnings per share over the last four quarters.
-
What is CRISPR Therapeutics AG's price-to-earnings ratio?
CRISPR Therapeutics AG (:CRSP) has a price-to-earnings ratio of -18.41 and price/earnings-to-growth ratio is -1.48.
